Published: 19 August 2021
Author(s): Kyle Staller, Ola Olén, Jonas Söderling, Bjorn Roelstraete, Hans Törnblom, Hamed Khalili, Mingyang Song, Jonas F Ludvigsson
Issue: January 2022
Section: Original article

Irritable bowel syndrome (IBS) affects 11.2% of the global population  [1], with significant impacts on patients’ quality of life despite no increased risk of mortality  [2]. Among this sizeable population, there is a disproportionate number of patients


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.